Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inarigivir soproxil - F-star Therapeutics

Drug Profile

Inarigivir soproxil - F-star Therapeutics

Alternative Names: GS 9992; Inarigivir; SB-9200

Latest Information Update: 23 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioHEP Technologies
  • Developer F-star Therapeutics; Gilead Sciences; National Institutes of Health (USA); Spring Bank Pharmaceuticals
  • Class Antivirals; Hepatoprotectants; Nucleotides; Small molecules
  • Mechanism of Action DDX58 protein stimulants; Immunomodulators; NOD2 protein agonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Discontinued Dengue; Hepatitis B; Hepatitis C; Hepatitis D; HIV infections; Japanese encephalitis; Norovirus infections; Respiratory syncytial virus infections; Tuberculosis; West Nile virus infections

Most Recent Events

  • 23 Mar 2023 Discontinued - Phase-I for Hepatitis C (Treatment-naive) in Australia (PO)
  • 23 Mar 2023 Discontinued - Phase-I for Hepatitis C (Treatment-naive) in New Zealand (PO)
  • 23 Mar 2023 Discontinued - Preclinical for Hepatitis C in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top